You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-NS-20-011 : RFA-NS-20-011

    Release Date: 10-01-2019Open Date: 12-08-2019 Due Dates: Multiple Close Date: 09-08-2022

    Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DK-21-021: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 06-25-2021Open Date: 01-17-2022 Due Dates: Multiple Close Date: 10-07-2022

    Early identification of T1D risk and the onset of autoimmunity provides the basis for a variety of major ongoing studies seeking to prevent or delay the disease. Ongoing research on the natural history of the development of T1D in at risk neonates has shown that early identification of those at risk can foster early diagnosis of T1D and avoid life-threatening diabetic ketoacidosis (DKA). It is est ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-DK-21-011: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-06-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite the availability of increasingly effective treatment modalities, including insulin analogues, continuous glucose monitors (CGMs), and continuous subcutaneous insulin infusion (CSII) devices, a substantial proportion of patients with type 1 diabetes (T1D) cannot achieve adequate glycemic control and avoid acute complications such as hypoglycemia. NIDDK has long supported this area of resear ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-DK-21-012: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

    Release Date: 05-19-2021Open Date: 02-09-2022 Due Dates: Multiple Close Date: 10-08-2022

    Despite clear progress made during the last 15 years on cellular transplantation for T1D, the most recent results demonstrate a long-term limited viability of engrafted islets and, as a result, limited insulin independence under different novel modalities of immunosuppressive (IS) regimens tested. In addition, even the most innovative IS regimens required for transplant survival still have signifi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PA-20-047: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)

    Release Date: 01-08-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2023

    Background Single cell analysis has recently become an active area of research to uncover fundamental biological principles behind cell diversity, which are often masked and not amenable to the population analysis of cells. The past several years have witnessed a rapid advancement in the development of single cell technologies and analysis methods. Multiple single cell "-omics" approaches are eme ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)

    Release Date: 03-30-2021Open Date: 05-26-2021 Due Dates: Multiple Close Date: 02-02-2023

    Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to innovate and develop the early commercial stages of novel technologies that will enable greater than a one order of magnitude improvement in DNA sequencing, or methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been great ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-20-111: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-02-2020Open Date: 07-11-2020 Due Dates: Multiple Close Date: 05-08-2023

    A. Overview Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food a ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)

    Release Date: 07-09-2021Open Date: 10-01-2021 Due Dates: Multiple Close Date: 06-16-2023

    Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to accelerate innovation and early development in the emerging field of single-molecule protein sequencing (SMPS). This FOA is seeking novel technologies or significant improvements to existing technologies. Exploration of technologies other than those currently being commercialized is highly encouraged. The s ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-059: linical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Bioma ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 11-19-2020Open Date: 01-22-2021 Due Dates: Multiple Close Date: 09-08-2023

    Background A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints, as well as composite biomarkers or biomarker signatures. Becaus ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government